Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review

ABSTRACT Pancreatic cancer is one of the tumors with poor prognosis and low survival due to late diagnosis, high resistance, and very limited effective therapeutic options. Thus, new pharmacological treatments are necessary to improve the prognosis of patients. In this context, nanoparticles represe...

Full description

Saved in:
Bibliographic Details
Published in:Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2024-11, Vol.16 (6), p.e2013-n/a
Main Authors: Lara, Patricia, Quiñonero, Francisco, Ortiz, Raul, Prados, Jose, Melguizo, Consolación
Format: Article
Language:English
Subjects:
Advanced Review
Animals
Cancer
Cancer therapies
Drug therapy
Effectiveness
Genetic Therapy
High resistance
Humans
Medical prognosis
Mice
Nanoparticles
Nanoparticles - chemistry
Pancreatic cancer
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - therapy
Prognosis
RNA, Small Interfering - therapeutic use
siRNA
Therapy
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Pancreatic cancer is one of the tumors with poor prognosis and low survival due to late diagnosis, high resistance, and very limited effective therapeutic options. Thus, new pharmacological treatments are necessary to improve the prognosis of patients. In this context, nanoparticles represent an efficient system for transporting and administering therapeutic molecules. Furthermore, siRNA can be used in cancer treatment to selectively inhibit the expression of any target gene. Therefore, nanoparticles associated with siRNA have been tested as a new therapeutic strategy to solve the pancreatic cancer treatment failure in the clinical setting. The current article presents a systematic revision of the literature of the last 10 years in which nanoparticles loading siRNA are used in pancreatic cancer. This research was carried out in three databases (PubMed, Scopus, and Web of Science) obtaining 164 articles from which 37 were selected. Our results show an overall view of the high effectiveness of this new therapy that combines nanoparticles with genetic therapy in pancreatic cancer suggesting that siRNA‐based medicines will likely open up a new therapeutic era in the treatment of this type of tumors. In this review, we introduce the most relevant therapeutic trials against pancreatic cancer using siRNA‐associated nanoparticles, provide examples of nanodrugs that have been developed for the treatment of this type of cancer, and summarize the in vitro and in vivo results.
ISSN:1939-5116
1939-0041
1939-0041
DOI:10.1002/wnan.2013